Anzeige
Meldung des Tages: 20-Milliarden-Markt vor dem Durchbruch: Dieser Drohnen-Player baut ein komplettes Luftfahrt-Ökosystem auf

Kazia Therapeutics Aktie (ADR) News

Aktie
WKN:  A4142V ISIN:  US48669G3039 US-Symbol:  KZIA Branche:  Biotechnologie Land:  Australien
8,00 $
-0,315 $
-3,79%
6,8885 € 14:33:03 Uhr
Depot/Watchlist
Marktkapitalisierung *
1,52 Mrd. €
Streubesitz
-
KGV
-
Faktor
0.002
Originalaktie
AU0000NRTDA2

Kazia Therapeutics Aktie (ADR) News

30.01.26 - PR Newswire
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2) PR Newswire
27.01.26 - PR Newswire
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-​Stage Metastatic Triple-​Negative Breast Cancer PR Newswire
08.01.26 - PR Newswire
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End PR Newswire
07.01.26 - PR Newswire
How $594B in Precision Tech is Cracking the Metastatic Cancer Code
How $594B in Precision Tech is Cracking the Metastatic Cancer Code PR Newswire
22.12.25 - PR Newswire
Kazia Therapeutics Regains Full Nasdaq Listing Compliance
Kazia Therapeutics Regains Full Nasdaq Listing Compliance PR Newswire
10.12.25 - PR Newswire
Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+
Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-​Tumor Immunity Across Multiple Advanced Breast ...
02.12.25 - PR Newswire
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities PR Newswire
18.11.25 - PR Newswire
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy
Kazia Therapeutics Achieves Initial iCR (Immune-​Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-...
27.10.25 - PR Newswire
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner PR Newswire
07.10.25 - PR Newswire
Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program
Kazia Therapeutics Announces Collaboration and In-​Licensing Agreement for First-​in-Class PD-L1 Protein Degrader Program PR Newswire
02.10.25 - PR Newswire
Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen
Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-​Access Case of Metastatic TNBC Patient Treated with Paxalisib-​Immunotherapy Regimen PR Newswire
01.10.25 - PR Newswire
Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG
Kazia Therapeutics Supports Australian MRFF-​Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG PR Newswire
11.09.25 - PR Newswire
Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy
Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy PR Newswire
01.08.25 - PR Newswire
Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market
Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market PR Newswire
10.07.25 - PR Newswire
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up PR Newswire
09.07.25 - PR Newswire
Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial
Kazia Therapeutics Reports Early Efficacy Data from First Triple-​Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating ...
11.06.25 - PR Newswire
Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)
Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-​Negative Breast Cancer ...
05.06.25 - PR Newswire
Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer
Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer PR Newswire
15.05.25 - PR Newswire
Kazia Therapeutics Highlights Recent Progress and Provides Business Update
Kazia Therapeutics Highlights Recent Progress and Provides Business Update PR Newswire

Newssuche

Videos

newspaper
04.03.26 -2,69%
ROHÖL mit Ziel MINUS 40$?!?
Fundierte Strategien für den Handel der wichtigen News in einem Seminarpaket, plus transparenter ... Mehr »